TASER International, Inc. 2011 Form 10-K Summary
Business context and reporting period
The filing is for TASER International, Inc., now known as Axon Enterprise, Inc., covering the fiscal year ended December 31, 2011. The company developed and sold electronic control devices, accessories, training services, and video evidence products, including TASER ECDs, AXON cameras, and EVIDENCE.COM software-as-a-service.
In the fourth quarter of 2011, management formally identified two reportable segments: ECD and Video. The Video segment included TASER Cam, AXON products, and EVIDENCE.COM. The filing is an audited annual report, not a standalone quarterly filing, although unaudited fourth-quarter data is presented.
Financial performance and liquidity
| Metric | 2011 | 2010 | Change |
|---|---|---|---|
| Net sales | $90.0 million | $86.9 million | +4% |
| Gross margin | $44.5 million; 49% | $45.4 million; 52% | Margin down 3 points |
| Operating loss | $10.9 million | $5.1 million | Loss increased $5.8 million |
| Net loss | $7.0 million | $4.4 million | Loss increased $2.7 million |
| Basic and diluted loss per share | $0.12 | $0.07 | Loss increased |
| Cash flow from operations | $17.3 million | $0.7 million | Improved $16.5 million |
| Cash and cash equivalents | $21.3 million | $42.7 million | Down $21.4 million |
| Total cash, cash equivalents and investments | $26.4 million | $42.7 million | Down $16.3 million |
| Working capital | $45.8 million | $70.4 million | Down $24.5 million |
| Total debt | None outstanding | None outstanding | No change |
ECD sales were $86.7 million, or 96% of total sales, while Video sales were $3.4 million, or 4%. ECD gross margin was $50.7 million, or 59%, compared with $47.4 million, or 58%, in 2010. Video gross margin was negative $6.2 million, compared with negative $2.0 million in 2010, primarily because of higher EVIDENCE.COM service delivery costs and inventory charges.
The TASER X2 generated $8.1 million of sales in its first year of shipments and represented 9% of total sales. Single-cartridge sales increased 15% to $25.4 million. TASER X26 sales declined to $37.3 million from $41.3 million, while TASER Cam sales declined 45% to $2.2 million. AXON and EVIDENCE.COM sales totaled $0.8 million.
Operating cash flow benefited from improved sales, lower operating expenses, working-capital releases, and noncash charges. Investing cash use was $7.6 million, including $5.5 million of net investment purchases and approximately $2.1 million for equipment and intangible assets. Financing cash use was $31.1 million, principally due to $32.5 million of share repurchases.
The company had a $10.0 million secured revolving credit facility, maturing June 30, 2013, with no borrowings outstanding at year-end. A fourth-quarter charge caused a fixed-charge coverage covenant violation; the company obtained a waiver in March 2012, restoring availability and excluding the relevant charge from future covenant calculations.
Material changes versus prior comparable periods
- Sales increased 4% from 2010, reversing part of the 17% decline recorded in 2010 versus 2009.
- The new X2 product contributed significantly to growth, but partially displaced X26, X3, XREP, and consumer product sales.
- Gross margin declined to 49% from 52%, primarily because of $3.7 million of excess inventory charges. Excluding those charges, management reported that gross margin would have been approximately $48.3 million.
- Sales, general and administrative expense declined 3% to $38.0 million, and research and development expense declined 12% to $10.0 million.
- Video operating losses increased substantially as EVIDENCE.COM moved from development into commercial service and incurred a full year of service delivery costs.
- The company recognized $3.7 million of excess inventory charges for TASER X3 and first-generation AXON inventory, plus $2.0 million of impairment or disposal charges for related tooling and equipment.
- The company repurchased 7.5 million shares for $32.5 million, reducing shares outstanding and materially consuming cash.
- Year-end inventory fell to $11.5 million from $17.8 million, while the excess and obsolete inventory reserve increased to $4.4 million from $0.4 million.
Fourth-quarter results and unusual items
| Quarter ended December 31 | 2011 | 2010 |
|---|---|---|
| Net sales | $21.3 million | $22.9 million |
| Gross margin | $7.0 million | $11.8 million |
| Net income (loss) | $(5.9) million | $(0.2) million |
| Basic and diluted EPS | $(0.11) | $0.00 |
The fourth quarter included $3.7 million of excess inventory charges related to TASER X3 and first-generation AXON products and $2.0 million of impairment of associated tooling. These charges contributed to the quarterly loss and the credit-facility covenant violation.
Guidance, outlook, commentary, and risks
The filing does not provide formal numerical revenue, earnings, or margin guidance. Management expected increased AXON and EVIDENCE.COM trial programs in 2012, continued growth in private-citizen sales, further development of next-generation ECD hardware, and continued refinement of AXON and EVIDENCE.COM. AXON Flex was introduced in early 2012, with customers that purchased certain 2011 orders given upgrade options.
- Growth depends heavily on law-enforcement, federal, military, corrections, and international adoption, where purchasing cycles can extend from weeks to several years and budgets are subject to political and fiscal constraints.
- The company remained substantially dependent on TASER X26, X2, and related cartridge sales. Product transitions may create inventory write-downs, lower margins, or demand displacement.
- The Video segment was not yet profitable and required substantial investment in data-center infrastructure, software maintenance, product development, and customer trials.
- Data security breaches, service outages, disasters, or migration to third-party cloud infrastructure could damage the EVIDENCE.COM business.
- The company faced substantial product-liability and wrongful-death litigation. A Turner case produced a $10 million jury verdict; the company recorded a $3.3 million reserve for its estimated uninsured exposure and continued post-trial challenges.
- The company reported 42 pending product-related lawsuits at year-end and ongoing patent disputes, including litigation involving Karbon Arms and other parties.
- Regulatory restrictions, export licensing, environmental requirements, product-safety perceptions, intellectual-property challenges, supply-chain interruptions, and foreign-currency movements could adversely affect results.
- One distributor represented 12.7% of 2011 sales, creating customer-concentration risk.
- The company maintained $2.0 million of unrecognized tax benefits and a $1.4 million valuation allowance against certain Arizona research and development tax credits.
Most important facts for investors to verify
- Confirm the company-name transition from TASER International, Inc. to Axon Enterprise, Inc. and ensure subsequent-period comparisons use consistent segment definitions.
- Assess whether X2 and later AXON Flex adoption offset declining legacy-product demand without causing further inventory charges or margin pressure.
- Track Video segment revenue growth, recurring EVIDENCE.COM revenue, service-delivery costs, and the timing of segment profitability.
- Review cash usage after the $32.5 million share repurchase and confirm compliance with the amended revolving-credit covenants.
- Monitor the Turner verdict, remaining product-liability claims, patent litigation, insurance coverage, and potential uninsured exposure.
- Evaluate the realizability of deferred tax assets and the resolution of approximately $2.0 million of unrecognized tax benefits.
- Verify distributor concentration, government-budget conditions, export restrictions, and customer adoption timelines.